NCT01003015View on ClinicalTrials.gov

Safety Study of BAY73-4506 in Patients With Hepatocellular Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

September 30, 2009

Primary Completion Date

November 30, 2010

Study Completion Date

March 31, 2013

Conditions
Carcinoma, Hepatocellular
Interventions
DRUG

BAY73-4506

160 mg BAY73-4506

Trial Locations (13)

20089

Rozzano

20122

Milan

20133

Milan

39112

Magdeburg

40138

Bologna

45122

Essen

55131

Mainz

60590

Frankfurt am Main

93042

Regensburg

00168

Roma

700-721

Daegu

135-710

Seoul

08036

Barcelona

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY